Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Astrocytoma 8Glioblastoma 5Recurrence 3Oligodendroglioma 2Neuroectodermal Tumors, Primitive 2Neurocytoma 2Glioma 2Brain Neoplasms 2Optic Nerve Glioma 1Neurofibroma 1Neuroblastoma 1Neurilemmoma 1Meningioma 1Gliosarcoma 1Ganglioglioma 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Central Nervous System Neoplasms 1

Interventions

mirdametinib 2tipifarnib 1talimogene laherparepvec 1peginterferon alfa-2b 1nilotinib 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Temozolomide 1Talaporfin 1Sirolimus 1Restraint, Physical 1Ranibizumab 1Radiosurgery 1Photochemotherapy 1Neurofibromin 1 1Mn-PyC3A 1Imatinib Mesylate 1Everolimus 1Elasticity Imaging Techniques 1Deoxycholic Acid 1Cryotherapy 1Celecoxib 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibroma × antineoplaston AS 2-1 × CNS × Clear all
NCT02988726 2017-07-26

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

Burzynski Research Institute

Phase 2 Terminated
3 enrolled
CNS

Neurilemmoma, Neurofibroma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡